Explore recent issues of Contract Pharma covering key industry trends.
Read the full digital version of our magazine online.
Stay informed! Subscribe to Contract Pharma for industry news and analysis.
Get the latest updates and breaking news from the pharmaceutical and biopharmaceutical industry.
Discover the newest partnerships and collaborations within the pharma sector.
Keep track of key executive moves and promotions in the pharma and biopharma industry.
Updates on the latest clinical trials and regulatory filings.
Stay informed with the latest financial reports and updates in the pharma industry.
Expert Q&A sessions addressing crucial topics in the pharmaceutical and biopharmaceutical world.
In-depth articles and features covering critical industry developments.
Access exclusive industry insights, interviews, and in-depth analysis.
Insights and analysis from industry experts on current pharma issues.
A detailed look at the leading US players in the global pharmaceutical and BioPharmaceutical industry.
Browse companies involved in pharmaceutical manufacturing and services.
Comprehensive company profiles featuring overviews, key statistics, services, and contact details.
A comprehensive glossary of terms used in the pharmaceutical and biopharmaceutical industry.
Watch in-depth videos featuring industry insights and developments.
Listen to expert discussions and interviews in pharma and biopharma.
Download in-depth eBooks covering various aspects of the pharma industry.
Access detailed whitepapers offering analysis on industry topics.
View and download brochures from companies in the pharmaceutical sector.
Explore content sponsored by industry leaders, providing valuable insights.
Stay updated with the latest press releases from pharma and biopharma companies.
Explore top companies showcasing innovative pharma solutions.
Meet the leaders driving innovation and collaboration.
Engage with sessions and panels on pharma’s key trends.
Hear from experts shaping the pharmaceutical industry.
Join online webinars discussing critical industry topics and trends.
A comprehensive calendar of key industry events around the globe.
Live coverage and updates from major pharma and biopharma shows.
Find advertising opportunities to reach your target audience with Contract Pharma.
Review the editorial standards and guidelines for content published on our site.
Understand how Contract Pharma handles your personal data.
View the terms and conditions for using the Contract Pharma website.
What are you searching for?
Addresses concerns regarding over-dependence on regional supply of pharma ingredients to the Western Pharma industry
September 18, 2018
By: Tim Wright
Lonza Pharma & Biotech has launched its pharmaceutical early-intermediates supply initiative. The initiative leverages chemical production facilities at the company’s Visp, Switzerland site to address increasing global early-intermediates supply security and quality concerns. Lonza now offers its customers an integrated supply chain from non-GMP early intermediates to cGMP advanced intermediates and active pharmaceutical ingredients (APIs). Lonza will supply ISO-certified early intermediates to customers under customized arrangements in order to simplify supply chains. These arrangements can be based on replacing current sources of non-GMP material, forward processing of basic or specialty chemicals, or back integrating current API supply. The seven ISO-certified plants within the Visp complex provide more than 600m3 of reactor volume and a full range of capabilities across an array of chemical technologies to service customer requirements. “Lonza’s Visp site is well positioned to help address our customers’ concerns over their API supply chain. As a world leader in API development and manufacturing, we have been diversifying and replacing our early-intermediates supply base with internally produced material,” said Michael Banks, vice president early intermediates, Lonza Pharma & Biotech. “We are now able to offer this early-intermediates supply option directly to customers under flexible arrangements that meet their specific needs.” Lonza has a well-established base for chemical synthesis at its Visp site with more than 40 years’ track record in the production of APIs and their intermediates. The Visp infrastructure includes an array of development, clinical scale and manufacturing capacity, capabilities and expertise for both small molecules and biologics. Lonza’s second small-molecule site in Nansha, China was built and operates to ICH standards for the development and manufacture of APIs, providing additional supply chain capability and flexibility to a global customer base. “We are dedicated to the high-quality, secure supply of intermediates and APIs for ensuring uninterrupted supply of life-saving medicines. We are also focused on innovation-across our technologies, services and business models-to help bring new medicines to market,” said Gordon Bates, president chemical division, Lonza Pharma & Biotech. “The launch of our early-intermediates initiative is another important chapter in pursuing this mission.”
Enter your account email.
A verification code was sent to your email, Enter the 6-digit code sent to your mail.
Didn't get the code? Check your spam folder or resend code
Set a new password for signing in and accessing your data.
Your Password has been Updated !